Search results
The Liver Forum: Facilitating Drug Development for the Treatment of Liver Disease. Background. Non-alcoholic fatty liver disease (NAFLD) comprising both non-alcoholic fatty liver (NAFL) and non-alcoholic steatohepatitis (NASH), has emerged as a leading cause of chronic liver disease.
Nonalcoholic Steatohepatitis (NASH) Guest. Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health.
29 sie 2024 · Learn more about nonalcoholic steatohepatitis (NASH) including symptoms, treatment, real patient stories, support, and more from a community perspective.
Non-alcoholic fatty liver disease and NASH Forum. Start new discussions to share your experience on the impact of NAFLD and NASH on your personal, family and professional life.
17 wrz 2021 · Nonalcoholic fatty liver disease (NAFLD) is characterized by evidence of hepatic steatosis as determined by either imaging or histology, associated with metabolic factors. Other liver diseases, such as alcoholic liver disease, viral liver disease, and drug-induced liver disorder are excluded.
23 lis 2017 · Nonalcoholic steatohepatitis, a type of liver damage that is strongly associated with visceral adiposity and the metabolic syndrome, has become a major cause of cirrhosis and liver cancer.
Importance Nonalcoholic steatohepatitis (NASH) is the inflammatory subtype of nonalcoholic fatty liver disease (NAFLD) and is associated with disease progression, development of cirrhosis, and need for liver transplant. Despite its importance, NASH is underrecognized in clinical practice.
